OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Free Publication in 2019
Current Issue: 2019  Archive: 2018 2017

Special Issue

Novel Concepts of Neurodegeneration in Parkinson's Disease

Submission Deadline: May 20, 2019 (Open)                Submit Now

Guest Editor

Tomohiro Chiba, MD, PhD
Assistant Professor, Department of Pathology, Kyorin University School of Medicine, Tokyo 181-8611, Japan
E-mail: [email protected]; [email protected]
Website: https://www.linkedin.com/in/tomohiro-chiba-55553a13; https://www.researchgate.net/profile/Tomohiro_Chiba
Research Interest: Alzheimer's disease; Parkinson's disease; ALS; Stat3; oncology; cell signaling

About This Topic

In the special issue, I would like to focus on the pathogenesis of Parkinson's disease (PD). Most PD cases can be improved by dopamine replacement and many strategies including iPS-based cell therapy have been proposed. Some PD patients, however, are still resistant to dopamine replacement, leading us to further understand the pathogenesis of PD. Especially, it is important to elucidate the pathogenetic mechanisms underlying neurodegeneration of PD. New therapeutic targets of PD will be found in the pursuit of detailed pathogenetic mechanisms. In the special issue, novel concepts of neurodegeneration in PD will be discussed. We welcome a variety of concepts such as cell death mechanisms, neuroinflammation, metablism, etc.